The Issue: Children with Osteosarcoma
When Zach Sobiech was 14 years old, he learned he had osteosarcoma, a bone cancer that can spread throughout the body. Instead of giving in to adversity, though, Zach turned to music. He began writing and performing songs as a way to not only spread awareness of his disease, but to say goodbye to friends and family. He inspired fans around the world and, when he passed away on May 20, 2013, his song “Clouds” rose to the top of iTunes, Spotify, and the Billboard charts.
Every year, the American Cancer Society reports, approximately 400 children in the United States are diagnosed with osteosarcoma. Nevertheless, researchers estimate their knowledge of sarcoma biology is as much as 30 years behind that of leukemia.
The Campaign: Funding Osteosarcoma Research
All donations to this Grassroots campaign will be used by Zach Sobiech Osteosarcoma Fund of Children’s Cancer Research Fund to support sarcoma research. Every $10 raised will help support a multi-year research program for better treatment and prevention in children and young adults. Each dollar spent on research helps to secure $18 of national funding.
Below is the video for Zach Sobiech’s song “Clouds”:
For another way to celebrate Zach and his music while supporting Children’s Cancer Research Fund, check out our Groupon Goods deal for his album Fix Me Up and his mother’s memoir, Fly a Little Higher. A portion of the proceeds will go to benefit the Fund.
Zach Sobiech Osteosarcoma Fund of Children's Cancer Research Fund
After Zach was diagnosed with osteosarcoma and began his musical journey, he and his family started the Zach Sobiech Osteosarcoma Fund of Children's Cancer Research Fund. Through this fund, proceeds from his sales and fundraisers funneled toward improving sarcoma treatments and prevention. In collaboration with Dr. Brenda Weigel, the fund is currently sponsoring a multi-year program to better understand the genetics of osteosarcoma. In the first year of the program, researchers hope to collect genetic information and identify which genes are most likely to metastasize. They're also testing genetic markers in children to predict who has the highest risk of contracting the disease, helping ensure earlier screening when initial signs appear. In the second year, researchers will experiment in altering the behavior of the cancerous cells and test drugs designed to target osteosarcoma. If the tests are successful, they can lead to Phase 1 clinical trials in children with the disease.